Phase II Study of SMILE Chemotherapy for Newly Diagnosed Stage IV, Relapsed, or Refractory Extranodal Natural Killer (NK)/T-Cell Lymphoma, Nasal Type: The NK-Cell Tumor Study Group Study

Yamaguchi, Motoko; Kwong, Yok-Lam; Seog Kim, Won; Maeda, Yoshinobu; Hashimoto, Chizuko; Suh, Cheolwon; Izutsu, Koji; Ishida, Fumihiro; Isobe, Yasushi; Sueoka, Eisaburo; Suzumiya, Junji; Kodama, Takao; Kimura, Hiroshi; Hyo, Rie; Nakamura, Shigeo; Oshimi, Kazuo; Suzuki, Ritsuro

doi:10.1200/jco.2011.35.6287

Public

Phase II Study of SMILE Chemotherapy for Newly Diagnosed Stage IV, Relapsed, or Refractory Extranodal Natural Killer (NK)/T-Cell Lymphoma, Nasal Type: The NK-Cell Tumor Study Group Study

Shared by NobleBlocks on Nov 20, 2011 • 12:00 AM UTC

Authors:

Motoko Yamaguchi

Yok-Lam Kwong

Won Seog Kim

Abstract

Purpose To explore a more effective treatment for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer/T-cell lymphoma, nasal type (ENKL), we conducted a phase II study of the steroid (dexamethasone), methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) regimen. Pat...

Discussions